These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Structural basis of antagonism of human APOBEC3F by HIV-1 Vif. Hu Y; Desimmie BA; Nguyen HC; Ziegler SJ; Cheng TC; Chen J; Wang J; Wang H; Zhang K; Pathak VK; Xiong Y Nat Struct Mol Biol; 2019 Dec; 26(12):1176-1183. PubMed ID: 31792451 [TBL] [Abstract][Full Text] [Related]
8. Defining HIV-1 Vif residues that interact with CBFβ by site-directed mutagenesis. Matsui Y; Shindo K; Nagata K; Io K; Tada K; Iwai F; Kobayashi M; Kadowaki N; Harris RS; Takaori-Kondo A Virology; 2014 Jan; 449():82-7. PubMed ID: 24418540 [TBL] [Abstract][Full Text] [Related]
9. Cellular requirements for bovine immunodeficiency virus Vif-mediated inactivation of bovine APOBEC3 proteins. Zhang W; Wang H; Li Z; Liu X; Liu G; Harris RS; Yu XF J Virol; 2014 Nov; 88(21):12528-40. PubMed ID: 25142583 [TBL] [Abstract][Full Text] [Related]
10. Core Binding Factor β Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation. Matsui Y; Shindo K; Nagata K; Yoshinaga N; Shirakawa K; Kobayashi M; Takaori-Kondo A J Biol Chem; 2016 Nov; 291(48):24892-24899. PubMed ID: 27758855 [TBL] [Abstract][Full Text] [Related]
11. Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components. Zhou X; Evans SL; Han X; Liu Y; Yu XF PLoS One; 2012; 7(3):e33495. PubMed ID: 22479405 [TBL] [Abstract][Full Text] [Related]
12. Identification of a tripartite interaction between the N-terminus of HIV-1 Vif and CBFβ that is critical for Vif function. Desimmie BA; Smith JL; Matsuo H; Hu WS; Pathak VK Retrovirology; 2017 Mar; 14(1):19. PubMed ID: 28302150 [TBL] [Abstract][Full Text] [Related]
13. Cyclin F/FBXO1 Interacts with HIV-1 Viral Infectivity Factor (Vif) and Restricts Progeny Virion Infectivity by Ubiquitination and Proteasomal Degradation of Vif Protein through SCF Augustine T; Chaudhary P; Gupta K; Islam S; Ghosh P; Santra MK; Mitra D J Biol Chem; 2017 Mar; 292(13):5349-5363. PubMed ID: 28184007 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G. Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650 [TBL] [Abstract][Full Text] [Related]
15. Identification of a Conserved Interface of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Vifs with Cullin 5. Gu Q; Zhang Z; Gertzen CGW; Häussinger D; Gohlke H; Münk C J Virol; 2018 Mar; 92(6):. PubMed ID: 29263270 [TBL] [Abstract][Full Text] [Related]
16. Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction. Gai Y; Duan S; Wang S; Liu K; Yu X; Yang C; Li G; Zhou Y; Yu B; Wu J; Wang C; Yu X Viruses; 2024 Mar; 16(4):. PubMed ID: 38675833 [TBL] [Abstract][Full Text] [Related]
17. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants. Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576 [TBL] [Abstract][Full Text] [Related]
19. Maedi-visna virus Vif protein uses motifs distinct from HIV-1 Vif to bind zinc and the cofactor required for A3 degradation. Knecht KM; Hu Y; Rubene D; Cook M; Ziegler SJ; Jónsson SR; Xiong Y J Biol Chem; 2021; 296():100045. PubMed ID: 33465707 [TBL] [Abstract][Full Text] [Related]
20. Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions. Azimi FC; Lee JE Protein Sci; 2020 Feb; 29(2):391-406. PubMed ID: 31518043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]